News
Men receiving tirzepatide showed greater reductions in body weight and waist circumference and improvements in erectile ...
Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes.
A new study in mice shows that tirzepatide—the active ingredient in the popular drugs Mounjaro and Zepbound—not only helps shed pounds but may also slow or reduce the growth of breast cancer tumors ...
Baseline BMI may play a significant role in improving exercise capacity, body weight and BP among patients with HF with ...
10h
News Medical on MSNChinese study shows lasting weight loss after tirzepatide treatmentObesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, hypertension, and cardiovascular disease.
Tirzepatide improves outcomes in patients with obesity-related HFpEF regardless of the severity of their baseline BMI or fat ...
Costa Rica: A recent systematic review published in the Cureus Journal of Medical Science has shed light on the potential of ...
A retrospective cohort study found that semaglutide and tirzepatide are linked with significantly lower risks of dementia and ...
15h
India Today on MSNWeight-loss drugs work, but here's when the weight starts to returnNew study reveals weight-loss drugs help during treatment but weight returns rapidly after stopping. Here's what they found.
16h
Verywell Health on MSNIs This 5-Ingredient 'Japanese Mounjaro' Drink Worth Trying for Weight Loss?Curious about the viral “Japanese Mounjaro” drink? Learn what it is, what it’s made of, and whether it can actually support ...
Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body weight, food intake and many measures of appetite more than placebo and ...
Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results